United States: License Agreement Diligence Obligations ‘Fuly’ Met For Fulyzaq®

On February 25, 2014, a jury sided in favor of Salix Pharmaceuticals that Salix met its contractual obligations under a license agreement with Napo Pharmaceuticals for the development of crofelemer (Fulyzaq®).  For business development professionals, lawyers and others who frequently work on license agreements, the most interesting issues were decided in pretrial rulings by the New York Supreme Court when the court on December 24, 2013 and January 29, 2014 granted summary judgment for Salix dismissing Napo's claims that Salix had breached the agreement by not using commercially reasonable efforts to develop crofelemer for indications other than the treatment of HIV-associated diarrhea (which is referenced throughout the remainder of this article as the "Main Indication") and for markets outside of the United States.

Key Agreement Provisions

They key provisions of the agreement at issue in the dispute were as follows (emphasis added):

Diligence Clauses

"Commercially Reasonable Efforts" means "...efforts and resources commonly used in the research-based pharmaceutical industry for an internally-developed product of similar commercial potential at a similar stage in its lifecycle, taking into consideration its safety and efficacy...and the likelihood of regulatory approval.  Commercially Reasonable Efforts shall be determined on a market-by-market basis for each Licensed Product without regard to the particular circumstances of a Party, including any other product opportunities of such Party...."

Section 2.1.1 – "Each of Napo and Salix shall use Commercially Reasonable Efforts to perform the Development activities designated for Napo or Salix, as the case may be, in the Development Plan and Budget, in accordance with the terms and conditions of this Agreement."

Section 9.1.1 – "As between the Parties, Salix shall have the sole right and obligation to Commercialize the Licensed Products in [all human fields in certain countries]." 

Section 9.1.2 – Salix, directly or through one or more Affiliates, Sublicensees or Distributors, shall use Commercially Reasonable Efforts to Commercialize a Licensed Product [for the Main Indication]."

Joint Steering Committee Clauses

Section 2.4 – "The Development of [crofelemer for the Main Indication] and of each Licensed Product for other indications as to which the Joint Steering Committee may determine to pursue Development activities, shall be governed by a comprehensive, multi-year plan and budget relating to such Development...."

Section 5.1.1, which gives Salix the right to name the Chairperson of the Joint Steering Committee.

Section 5.1.2(a), which requires the Joint Steering Committee to establish a strategy for development and commercialization of Licensed Products in not only the Main Indication but also other fields.

Section 5.1.2(b), which provided that in the event the Joint Steering Committee cannot agree on any matter, then the decision "shall be finally and definitively resolved by the Chairperson."

Section 9.1.3, which required Salix to submit a preliminary Commercialization plan to include forecasts and marketing and other commercialization activities but only for crofelemer for the Main Indication, plus any other matters or activities determined by the Joint Steering Committee.

Court's Analysis

In disposing of Napo's claims that Salix should have pursued development in other indications and countries outside the United States, the court pointed to the provision in Section 2.1.1, which limits the parties' obligations to perform development activities "designated in the Development Plan and Budget."  It also referenced Section 2.4, which requires the Development Plan and Budget to include development of crofelemer for the Main Indication and any other indications which the Joint Steering Committee may elect.  Since the Development Plan and Budget included development activities only for the Main Indication and only with respect to the United States, and the Joint Steering Committee did not elect to pursue any other indications or any other countries, the court found that as a matter of fact Salix has no obligation to pursue crofelemer for any other indications or countries. The agreement grants to Salix the right to name the chairperson to the Joint Steering Committee, and, according to the court, the chairperson has "final and absolute discretion regarding whether and when to pursue development of [other indications]."

The court specifically addressed the fact that Salix's license rights are broader than the Main Indication, and explained that a broader license may be justified in order to exclude competitors in other indications for use of the same product.

One of Napo's main arguments was that Section 9.1.1 provides an obligation for Salix to use commercially reasonable efforts to commercialize the licensed products in other fields and territories outside of the United States.  The court was not persuaded by this argument because it interpreted Section 9.1.1 as merely assigning responsibility between the parties.  It also said that if Section 9.1.1 required Salix to use commercially reasonable efforts in all indications, it would directly conflict with Section 9.1.2, which limits Salix's obligation to commercialize only for the Main Indication.


This case provides a number of lessons for business development professionals, attorneys and others who structure and draft license agreements, including the following:

  • If a licensor intends for the licensee to have an obligation to pursue multiple uses or to commercialize in multiple territories, the agreement should include clear obligations to do so.
  • Commercially reasonable efforts to develop and commercialize a product for a particular indication or use in a particular territory may not imply an obligation to develop and commercialize the product for any other uses or territories, even if the license grant extends to other uses and territories.
  • Commercially reasonable efforts to develop and commercialize a product in accordance with a development or commercialization plan, where the licensee can control the development or commercialization plan contents, may provide significant latitude to the licensee with respect to diligence obligations.
  • Establishing a joint steering or other committee structure where the licensee has final decision-making authority may be similar in effect with respect to diligence obligations to a structure where there is no committee and the licensee controls all decision-making.

For a copy of the New York Supreme Court decisions, a redacted version of the agreement between Salix and Napo, or other materials relating to this case, please contact David A. Charapp.

This article is for general information and does not include full legal analysis of the matters presented. It should not be construed or relied upon as legal advice or legal opinion on any specific facts or circumstances. The description of the results of any specific case or transaction contained herein does not mean or suggest that similar results can or could be obtained in any other matter. Each legal matter should be considered to be unique and subject to varying results. The invitation to contact the authors or attorneys in our firm is not a solicitation to provide professional services and should not be construed as a statement as to any availability to perform legal services in any jurisdiction in which such attorney is not permitted to practice.

Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. The Duane Morris Institute provides training workshops for HR professionals, in-house counsel, benefits administrators and senior managers.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.